Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes

Author:

Chen Rou-Zhen1,Lu Po-Liang123,Yang Tsung-Ying4567,Lin Shang-Yi18,Tang Hung-Jen9,Chang Feng-Yee10,Yang Ya-Sung10,Chiang Tsung-Ta10,Wang Fu-Der11,Wu Ting-Shu12ORCID,Shie Shian-Sen12,Ho Mao-Wang13,Liu Jien-Wei1415,Shi Zhi-Yuan16,Chou Chia-Hui13ORCID,Chuang Yin-Ching17

Affiliation:

1. School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan

2. Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital , Kaohsiung , Taiwan

3. Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University , Kaohsiung , Taiwan

4. Department of Medical Laboratory Science, I-Shou University , Kaohsiung , Taiwan

5. Research Organization for Nano and Life Innovation, Future Innovation Institute, Waseda University , Tokyo, Japan

6. Research Institute for Science and Engineering, Waseda University , Tokyo , Japan

7. School of Education, Waseda University , Tokyo , Japan

8. Infection Control Office and Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan

9. Division of Infectious Diseases, Department of Medicine, Chi Mei Medical Center , Tainan , Taiwan

10. Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center , Taipei , Taiwan

11. Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming Chiao Tung University , Taipei , Taiwan

12. Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital , Taoyuan , Taiwan

13. Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital , Taichung , Taiwan

14. Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital , Kaohsiung , Taiwan

15. Chang Gung University College, School of Medicine , Taoyuan , Taiwan

16. Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung , Taiwan

17. Department of Medical Research, Chi Mei Medical Center , Tainan , Taiwan

Abstract

Abstract Objective We aimed to assess the efficacy of cefoperazone/sulbactam (CPZ/SUL) in extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections and identify factors influencing outcomes. Methods This retrospective multicentre study was conducted in Taiwan (January 2015 to December 2020) and examined the efficacy of CPZ/SUL treatment in ESBL-producing Enterobacterales bacteraemia. The minimum inhibitory concentrations (MICs) were determined using agar dilution; ESBL/AmpC genes were detected using polymerase chain reaction. The primary outcome was clinical success, whereas the secondary outcome was 30-day mortality. Clinical success was defined as the complete resolution of clinical signs and symptoms of K. pneumoniae or E. coli infection, with no evidence of persistent or recurrent bacteraemia. The factors influencing outcomes were identified using a multivariate analysis. Results CPZ/SUL demonstrated a clinical success rate of 82.7% (91/110) in treating ESBL-producing Enterobacterales bacteraemia, with a 30-day mortality rate of 9.1% (10/110). Among 110 ESBL-producing isolates, a high clinical success rate was observed at an MIC of ≤32/32 mg/L. Multivariate analysis revealed that a Charlson comorbidity index (CCI) of ≥6 was associated with lower clinical success [odds ratio (OR): 5.80, 95% confidence interval (CI): 1.15–29.14, P = 0.033]. High Sequential Organ Failure Assessment scores (≥6) were significantly associated with increased 30-day mortality (OR: 14.34, 95% CI: 1.45–141.82, P = 0.023). Discussion CPZ/SUL demonstrated a clinical success rate of 82.7% (91/110) in treating ESBL-producing Enterobacterales bacteraemia. Treatment success was evident when the CPZ and SUL MIC was ≤32/32 mg/L. Comorbidities (CCI ≥6) were associated with lower clinical success, while disease severity (Sequential Organ Failure Assessment score ≥6) correlated with higher mortality.

Funder

TTY Biopharm Company

Publisher

Oxford University Press (OUP)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3